HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Sept. 28, 2015 (HealthDay News) -- Selective removal of circulating soluble Fms-like tyrosine kinase-1 (sFlt-1) with an extracorporeal device seems to be safe and effective for treating women with very preterm preeclampsia, according to a pilot study published online Sept. 24 in the Journal of the American Society of Nephrology.
Ravi Thadhani, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues conducted an open pilot study to evaluate the safety and potential efficacy of therapeutic apheresis with a plasma-specific dextran sulfate column to remove circulating sFlt-1 in 11 pregnant women (20 to 38 years of age) with very preterm preeclampsia (23 to 32 weeks' gestation).
The researchers found that mean sFlt-1 levels were reduced by 18 percent, with simultaneous reductions of 44 percent in protein/creatinine ratios. Compared to 22 untreated contemporaneous preeclampsia controls, pregnancy continued longer in women treated once and multiple times (three days versus eight and 12 days, respectively). Withholding preapheresis antihypertensive therapy, saline prehydration, and reducing blood flow through the apheresis column were used to manage transient maternal BP reduction during apheresis. No adverse effects of apheresis were observed when comparing infants born prematurely to untreated women with and without preeclampsia (22 patients per group).
"Therapeutic apheresis reduced circulating sFlt-1 and proteinuria in women with very preterm preeclampsia and appeared to prolong pregnancy without major adverse maternal or fetal consequences," the authors write. "A controlled trial is warranted to confirm these findings."
Several authors disclosed financial ties to diagnostics companies, including Kaneka Corporation, which funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022